Research Peptides Cyprus - HPLC-Verified | Regena

Sourcing research peptides in Cyprus has historically meant choosing between under-documented offshore suppliers, opaque domestic re-sellers and compounding pharmacies pricing well above research-budget tolerances. Regena replaces all three with a verified-batch supply chain operated from inside the European Union: every vial ships with an independent third-party HPLC and mass-spectrometry COA, tracked tracked 3–5 working day courier service across CY, and a research-use declaration that satisfies customs handling on entry.

For CY laboratories the practical effect is shorter project timelines and cleaner experimental risk. A batch ordered Monday is typically on the bench within the week, with the COA already cross-referenced against the vial cap batch number. There is no compounding-pharmacy markup, no anonymous reseller in the middle of the chain, and no week-long wait for analytical paperwork after dispatch.

The full Regena catalogue is available for Cyprus delivery — GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide), growth-hormone secretagogues (CJC-1295, ipamorelin, tesamorelin, MK-677 reference material), regenerative compounds (BPC-157, TB-500, GHK-Cu, KPV), mitochondrial peptides (MOTS-c, SS-31) and the wider research catalogue. Vials are 2 mg, 5 mg, 10 mg and 15 mg formats depending on the compound.

Every CY shipment includes the printed COA, batch number, lot number and compound-specific reconstitution guidance. Bacteriostatic water, sterile water, mixing vials and insulin syringes can be added to the same order so a CY bench has everything it needs for a complete reconstitution workflow on arrival.

CY orders ship tracked from our European hub with a standard transit window of 3–5 working day. Dispatched from inside the EU customs union — no import duties, no VAT surprises and no border holds on Cyprus delivery. Vials travel in temperature-buffered mailers sized for the CY transit window so lyophilised product arrives within specification; refrigerate at 2–8 °C on arrival.

Express courier options are available through the consultations team for CY laboratories on tight project timelines. Delivery covers all of Cyprus including Nicosia, Limassol, Larnaca and the broader Cypriot research community. Residential, co-working and registered research-entity addresses are all accepted.

Regena peptides are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Cyprus, and are not dispensed against a prescription. Cyprus research-use peptide supply sits outside Pharmaceutical Services-licensed medicinal-product regulation; nothing on the Regena catalogue is authorised by Pharmaceutical Services for human use. The research-use declaration ships with every CY package and is sufficient for the courier and any internal procurement record.

CY researchers should ensure their work complies with the relevant institutional ethics framework and any local research-material handling rules. The Regena consultations team can pre-clear documentation questions before any vial is dispatched.

Every batch shipped to Cyprus ties back to an independent third-party COA hosted on the Regena lab reports page. Janoshik Analytical is the default verifier — the most widely cited independent peptide laboratory in Europe — with orthogonal laboratories used when batch chemistry calls for confirmation by a second method or when a CY institution requires a specific accredited laboratory.

Minimum specification for release is ≥99.0% HPLC main peak with matching mass-spectrometry molecular weight and water content within the published specification for the compound. Batches that do not meet the specification are not released, regardless of supply pressure on the CY channel.

Cyprus hosts a focused biomedical research community anchored in the University of Cyprus, the Cyprus Institute of Neurology and Genetics and the European University Cyprus School of Medicine, and Regena's batch documentation slots directly into CY institutional procurement and ethics workflows.

For multi-batch CY programmes — longitudinal stability studies, comparator panels, multi-cohort protocols — the consultations team will reserve inventory against a project timeline so an institutional buyer is not exposed to the wider catalogue's shifting availability. Material Safety Data Sheets, Certificates of Origin and Certificates of Conformity are supplied on request before dispatch.

Lyophilised peptides delivered to Cyprus should be held at 2–8 °C on arrival; long-term storage at −20 °C is appropriate for batches that will not be reconstituted within 8–12 weeks. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a 28-day in-use stability window under refrigeration for most analogues — single-day work can use sterile water but should not be saved for repeat use.

Aliquot before any freeze. The single most common cause of measurable potency loss in long-acting analogues — semaglutide, tirzepatide, retatrutide — is repeat freeze-thaw cycling. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers compound-specific stability windows for CY laboratories.

A free 20-minute consultation is available to every CY researcher. The call covers compound selection, batch availability, COA review, reconstitution workflow and any project-specific stability or sourcing questions. The Regena scientific team handles consultations directly — there is no sales tier between a CY laboratory and the people who release the batch.

Book through the /consultations page; the team responds within one working day. For urgent CY requests, the same channel handles express dispatch quotes, inventory reservations and bespoke documentation requests.